Prof. Durbeej-Hjalt is a leading researcher in the field of neuromuscular disorders, serving as a professor at Lund University's Department of Experimental Medical Science in Sweden. She is head of the Muscle Biology unit, where her team focuses on understanding and developing treatments for laminin α2 chain-deficient congenital muscular dystrophy (LAMA2-MD).

Her research has significantly advanced the understanding of LAMA2-MD. Her work includes exploring genetic and pharmacological interventions to improve patient outcomes. Additionally, she has contributed to international workshops and publications, collaborating with experts worldwide to address challenges in treating rare neuromuscular diseases.

Beyond her research, Prof. Durbeej-Hjalt has held leadership roles, including serving as the Secretary General for Medicine and Health at the Swedish Research Council. She is also the national representative of several international organisations, including the European Rare Disease Research Alliance (ERDERA). Her extensive experience and dedication continue to influence the field of neuromuscular research and therapy development.